Fresenius Group Overview

November 22, 2021

Fresenius Helios acquires oncological center and ophthalmic clinic in Colombia

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed agreements to acquire Centro Oncológico de Antioquia (COA) and Clínica Clofán, further expanding the company’s presence in Colombia. The clinics, located in Colombia's second largest city Medellín, will become part of Quirónsalud’s existing healthcare network in the country, which already comprises six hospitals and ten diagnostic centers.

COA is specialized in the diagnosis and treatment of cancer. It has 75 beds, four operating rooms, and specialized centers for nuclear medicine, radiotherapy and bone marrow transplants. Clínica Clofán is the second largest ophthalmic center in the city, with ten operating rooms and further dedicated facilities for treating even severe ophthalmic diseases and performing complex procedures.

Both clinics offer state-of-the-art medical standards and technology to their patients and are regarded as leading medical facilities with highly renowned physicians. Together they generate sales of around €30 million.

The acquisition is another important step in strengthening Fresenius Helios’ presence in the growing and consolidating healthcare services markets in Latin America.

The transaction is expected to close in the first quarter of 2022, pending anti-trust clearance of the Colombian authorities. Fresenius Helios expects the acquisition to be accretive to Fresenius’ Group net income  already in fiscal year 2022.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.